JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257963

Human GBP2 knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

GBP2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 103 bp deletion in exon6.

View Alternative Names

GTP-binding protein 2, Guanine nucleotide binding protein 2, Guanylate binding protein 2 interferon inducible, HuGBP 2, Interferon induced guanylate binding protein 2

2 Images
Western blot - Human GBP2 knockout A549 cell lysate (AB257963)
  • WB

Unknown

Western blot - Human GBP2 knockout A549 cell lysate (AB257963)

Lane 1 : Wild-type A549 cell lysate (20 ug)
Lane 2 : GBP2 knockout A549 cell lysate (20 ug)
Lane 3 : K-562 cell lysate (20 ug)
Lane 4 : HaCaT cell lysate (20 ug)

ab179829 was shown to specifically react with GBP2 in wild-type A549 cells. Loss of signal was observed when knockout cell line ab267219 (knockout cell lysate ab257963) was used. Wild-type and GBP2 knockout samples were subjected to SDS-PAGE. ab179829 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4oC at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

false

Sanger Sequencing - Human GBP2 knockout A549 cell lysate (AB257963)
  • Sanger seq

Unknown

Sanger Sequencing - Human GBP2 knockout A549 cell lysate (AB257963)

Homozygous : 103 bp deletion in exon6

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 103 bp deletion in exon6.

Disease

Carcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257963-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human GBP2 knockout A549 cell lysate", "number":"AB257963-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB257963-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
GBP2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

GBP2 also known as Guanylate Binding Protein 2 is a member of the dynamin superfamily of large GTPases. It has an approximate mass of 67 kDa. This protein finds expression predominantly in macrophages and other immune cells. The involvement of GBP2 in cellular defense mechanisms reflects its upregulation by interferon-gamma where it takes part in immune responses against microbial and viral infections.
Biological function summary

Guanylate Binding Protein 2 participates in immune response regulation. It does not function as part of a large multiprotein complex but acts primarily as a monomer. GBP2 disrupts pathogenic molecular machinery by binding to microbial enzymes leading to their inhibition which limits pathogen survival. This mechanism ensures that GBP2 remains a significant factor in the cell's intrinsic ability to fight infections at the molecular level.

Pathways

Guanylate Binding Protein 2 plays an important role in the interferon-induced defense pathways. It participates in the immune effector pathways primarily connecting to processes like the JAK-STAT signaling pathway. Through this involvement GBP2 helps enhance the expression of a variety of immunologically relevant genes. Additionally GBP2 often interacts with other members of the GBP family including GBP1 and GBP5 to amplify immune responses and signaling cascades.

Guanylate Binding Protein 2 shows a significant connection to infectious diseases like tuberculosis and viral infections such as hepatitis C. Overexpression or dysregulation of GBP2 can influence the progression and severity of these conditions. Additionally GBP2's interaction with proteins involved in inflammatory responses such as other interferon-induced proteins highlights its influence over auto-inflammatory conditions and its potential as a biomarker for disease progression.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB179829

Anti-GBP2 antibody [EPR13206] - N-terminal

RabMAb|Recombinant|KO Validated

Western blot - Anti-GBP2 antibody [EPR13206] - N-terminal (AB179829)

  • 0
  • 0
Proteins & Peptides

AB288799

Recombinant Human VCAM1 protein (Active)

Premium Bioactive

Biological Activity - Recombinant Human VCAM1 protein (Active) (AB288799)

  • 0
  • 0
Proteins & Peptides

AB259412

Recombinant human VEGF 165A protein (Active)

Premium Bioactive

Mass Spectrometry - Recombinant human VEGF 165A protein (Active) (AB259412)

  • 0
  • 0
Primary Antibodies

AB216347

Anti-SNAIL antibody [EPR21043]

20ul selling size|KO Validated|RabMAb|Recombinant

Western blot - Anti-SNAIL antibody [EPR21043] (AB216347)

  • 1
  • 1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com